Published in Medical Letter on the CDC and FDA, May 10th, 2006
In addition, the NLA recommends a review of these requirements by the U.S. Food & Drug Administration (FDA) and others.
"The problem is not that too many patients are having too many side effects. The problem is that too many patients are not being treated to reduce their risk of heart disease - the number one killer of both men and women in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.